Literature DB >> 18563785

Survival benefit in a randomized clinical trial of faecal occult blood screening for colorectal cancer.

E Lindholm1, H Brevinge, E Haglind.   

Abstract

BACKGROUND: Early detection of colorectal cancer could reduce cancer-specific mortality. The aim of this trial was to evaluate the effect of faecal occult blood test (FOBT) screening on colorectal cancer mortality in a Swedish population.
METHODS: All 68,308 citizens in Göteborg born between 1918 and 1931 were randomized to a screening or a control group at the age of 60-64 years. All were screened two to three times with rehydrated Hemoccult-II. Compliance was 70.0 per cent (23,916 individuals). Those with a positive test result were offered sigmoidoscopy and a double-contrast enema. The primary endpoint was death from colorectal cancer.
RESULTS: After a mean of 9 years from the last screening, there was a significant reduction in colorectal cancer mortality in the screening group compared with the control group. The overall risk ratio of death from colorectal cancer was 0.84 (95 per cent confidence interval 0.71 to 0.99). The groups did not differ in incidence of colorectal cancer or in overall mortality.
CONCLUSION: FOBT screening significantly reduces colorectal cancer mortality. (c) 2008 British Journal of Surgery Society Ltd. Published by John Wiley & Sons, Ltd.

Entities:  

Mesh:

Year:  2008        PMID: 18563785     DOI: 10.1002/bjs.6136

Source DB:  PubMed          Journal:  Br J Surg        ISSN: 0007-1323            Impact factor:   6.939


  82 in total

Review 1.  Population-based screening for colorectal cancer with faecal occult blood test--do we really have enough evidence?

Authors:  Göran Ekelund; Jonas Manjer; Sophia Zackrisson
Journal:  Int J Colorectal Dis       Date:  2010-07-30       Impact factor: 2.571

2.  The Relationship between the Methylated Septin-9 DNA Blood Test and Stool Occult Blood Test for Diagnosing Colorectal Cancer in Taiwanese People.

Authors:  Chung-Hung Chen; Sheng-Lei Yan; Tsung-Hsun Yang; Shih-Feng Chen; Yung-Hsiang Yeh; Jing-Jim Ou; Chien-Hua Lin; Yueh-Tsung Lee; Chien-Hua Chen
Journal:  J Clin Lab Anal       Date:  2016-07-08       Impact factor: 2.352

Review 3.  Screening for colorectal cancer using the faecal occult blood test, Hemoccult.

Authors:  P Hewitson; P Glasziou; L Irwig; B Towler; E Watson
Journal:  Cochrane Database Syst Rev       Date:  2007-01-24

Review 4.  FIT testing: an overview.

Authors:  Lukejohn W Day; Taft Bhuket; James Allison
Journal:  Curr Gastroenterol Rep       Date:  2013-11

Review 5.  Stool Based Testing for Colorectal Cancer: an Overview of Available Evidence.

Authors:  Kevin M Rank; Aasma Shaukat
Journal:  Curr Gastroenterol Rep       Date:  2017-08

6.  External Validation of Risk Prediction Models Incorporating Common Genetic Variants for Incident Colorectal Cancer Using UK Biobank.

Authors:  Catherine L Saunders; Britt Kilian; Deborah J Thompson; Luke J McGeoch; Simon J Griffin; Antonis C Antoniou; Jon D Emery; Fiona M Walter; Joe Dennis; Xin Yang; Juliet A Usher-Smith
Journal:  Cancer Prev Res (Phila)       Date:  2020-02-18

Review 7.  Molecular markers for colorectal cancer screening.

Authors:  Brandon T Dickinson; John Kisiel; David A Ahlquist; William M Grady
Journal:  Gut       Date:  2015-05-20       Impact factor: 23.059

Review 8.  Stool Investigations for Colorectal Cancer Screening: From Occult Blood Test to DNA Analysis.

Authors:  Andrea Iannone; Giuseppe Losurdo; Maria Pricci; Bruna Girardi; Antonio Massaro; Mariabeatrice Principi; Michele Barone; Enzo Ierardi; Alfredo Di Leo
Journal:  J Gastrointest Cancer       Date:  2016-06

9.  Factors that contribute to faecal cyclooxygenase-2 mRNA expression in subjects with colorectal cancer.

Authors:  Y Hamaya; K Yoshida; T Takai; M Ikuma; A Hishida; S Kanaoka
Journal:  Br J Cancer       Date:  2010-02-09       Impact factor: 7.640

10.  Effect of repeated invitations on uptake of colorectal cancer screening using faecal occult blood testing: analysis of prevalence and incidence screening.

Authors:  R J C Steele; I Kostourou; P McClements; C Watling; G Libby; D Weller; D H Brewster; R Black; F A Carey; C Fraser
Journal:  BMJ       Date:  2010-10-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.